JP2015514056A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514056A5 JP2015514056A5 JP2014561567A JP2014561567A JP2015514056A5 JP 2015514056 A5 JP2015514056 A5 JP 2015514056A5 JP 2014561567 A JP2014561567 A JP 2014561567A JP 2014561567 A JP2014561567 A JP 2014561567A JP 2015514056 A5 JP2015514056 A5 JP 2015514056A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- compound
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 56
- 125000000753 cycloalkyl group Chemical group 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- -1 perhaloalkyl Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- QTFKWKHMQRDTEX-UHFFFAOYSA-N 1-[3-(azetidin-1-yl)phenyl]-3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7-trione Chemical compound O=C1N(C2CC2)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1N1CCC1 QTFKWKHMQRDTEX-UHFFFAOYSA-N 0.000 claims 2
- INCFHKIEZKOEIV-UHFFFAOYSA-N 3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-1-[3-(oxetan-3-yloxy)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione Chemical compound O=C1N(C2CC2)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1OC1COC1 INCFHKIEZKOEIV-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims 1
- JKPBUKGOABAHHL-UHFFFAOYSA-N 1-(3-cyclopropylsulfonylphenyl)-5-(2-fluoro-4-iodoanilino)-3,6,8-trimethylpyrido[4,3-d]pyrimidine-2,4,7-trione Chemical compound O=C1N(C)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1S(=O)(=O)C1CC1 JKPBUKGOABAHHL-UHFFFAOYSA-N 0.000 claims 1
- VGGYBSBVXSFLEE-UHFFFAOYSA-N 1-(3-cyclopropylsulfonylphenyl)-5-(2-fluoro-4-iodoanilino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7-trione Chemical compound O=C1NC(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1S(=O)(=O)C1CC1 VGGYBSBVXSFLEE-UHFFFAOYSA-N 0.000 claims 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims 1
- MICUMJRREWTXPP-UHFFFAOYSA-N 1-[3-(azetidin-1-yl)phenyl]-5-(2-fluoro-4-iodoanilino)-3,6,8-trimethylpyrido[4,3-d]pyrimidine-2,4,7-trione Chemical compound O=C1N(C)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1N1CCC1 MICUMJRREWTXPP-UHFFFAOYSA-N 0.000 claims 1
- WWQPFZMFTXTVLU-UHFFFAOYSA-N 1-[3-(cyclopropanecarbonyl)phenyl]-3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7-trione Chemical compound O=C1N(C2CC2)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1C(=O)C1CC1 WWQPFZMFTXTVLU-UHFFFAOYSA-N 0.000 claims 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims 1
- ZKDUPXPALSNJDR-UHFFFAOYSA-N 3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-5-[3-(3-hydroxyazetidin-1-yl)anilino]-6,8-dimethylpyrido[2,3-d]pyrimidine-2,4,7-trione Chemical compound C=1C=C(I)C=C(F)C=1N1C(=O)N(C2CC2)C(=O)C2=C1N(C)C(=O)C(C)=C2NC(C=1)=CC=CC=1N1CC(O)C1 ZKDUPXPALSNJDR-UHFFFAOYSA-N 0.000 claims 1
- VWKZOIVWIMPNMS-UHFFFAOYSA-N 3-cyclopropyl-1-(3-cyclopropylsulfonylphenyl)-5-(2-fluoro-4-iodoanilino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7-trione Chemical compound O=C1N(C2CC2)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1S(=O)(=O)C1CC1 VWKZOIVWIMPNMS-UHFFFAOYSA-N 0.000 claims 1
- ZYCVEDVDIMHMDQ-UHFFFAOYSA-N 3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-1-[3-(oxetan-3-ylamino)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione Chemical compound O=C1N(C2CC2)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1NC1COC1 ZYCVEDVDIMHMDQ-UHFFFAOYSA-N 0.000 claims 1
- ZMNFCBOTEZOZDX-UHFFFAOYSA-N 5-(2-fluoro-4-iodoanilino)-1-[3-(3-fluorooxetan-3-yl)phenyl]-3,6,8-trimethylpyrido[4,3-d]pyrimidine-2,4,7-trione Chemical compound O=C1N(C)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1C1(F)COC1 ZMNFCBOTEZOZDX-UHFFFAOYSA-N 0.000 claims 1
- RHHKRZPZIMWRGZ-UHFFFAOYSA-N 5-(2-fluoro-4-iodoanilino)-1-[3-(3-hydroxyoxetan-3-yl)phenyl]-3,6,8-trimethylpyrido[4,3-d]pyrimidine-2,4,7-trione Chemical compound O=C1N(C)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1C1(O)COC1 RHHKRZPZIMWRGZ-UHFFFAOYSA-N 0.000 claims 1
- MKZMOEHKSGBUFU-UHFFFAOYSA-N 5-(2-fluoro-4-iodoanilino)-3,6,8-trimethyl-1-[3-(oxetan-3-ylamino)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione Chemical compound O=C1N(C)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1NC1COC1 MKZMOEHKSGBUFU-UHFFFAOYSA-N 0.000 claims 1
- OLUSILLRZLWXOF-UHFFFAOYSA-N 5-(2-fluoro-4-iodoanilino)-3,6,8-trimethyl-1-[3-(oxetan-3-yloxy)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione Chemical compound O=C1N(C)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1OC1COC1 OLUSILLRZLWXOF-UHFFFAOYSA-N 0.000 claims 1
- LZKSNXWQOJKRJA-UHFFFAOYSA-N 5-(2-fluoro-4-iodoanilino)-3,6,8-trimethyl-1-[3-(oxetan-3-yloxymethyl)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione Chemical compound O=C1N(C)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1COC1COC1 LZKSNXWQOJKRJA-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229940126657 Compound 17 Drugs 0.000 claims 1
- JJWSNOOGIUMOEE-UHFFFAOYSA-N Monomethylmercury Chemical compound [Hg]C JJWSNOOGIUMOEE-UHFFFAOYSA-N 0.000 claims 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 229940125773 compound 10 Drugs 0.000 claims 1
- 229940125797 compound 12 Drugs 0.000 claims 1
- 229940126543 compound 14 Drugs 0.000 claims 1
- 229940125758 compound 15 Drugs 0.000 claims 1
- 229940126142 compound 16 Drugs 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 229940125810 compound 20 Drugs 0.000 claims 1
- 229940126086 compound 21 Drugs 0.000 claims 1
- 229940126214 compound 3 Drugs 0.000 claims 1
- 229940125898 compound 5 Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- BYRWTTNIKQXXSH-UHFFFAOYSA-N n-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]-3-methyloxetane-3-carboxamide Chemical compound O=C1N(C2CC2)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1NC(=O)C1(C)COC1 BYRWTTNIKQXXSH-UHFFFAOYSA-N 0.000 claims 1
- IYPOIMMRHWHYNL-UHFFFAOYSA-N n-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]azetidine-3-carboxamide Chemical compound O=C1N(C2CC2)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1NC(=O)C1CNC1 IYPOIMMRHWHYNL-UHFFFAOYSA-N 0.000 claims 1
- AWELVSKDGIEZGP-UHFFFAOYSA-N n-[3-[5-(2-fluoro-4-iodoanilino)-3,6,8-trimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]-3-methyloxetane-3-carboxamide Chemical compound O=C1N(C)C(=O)C2=C(NC=3C(=CC(I)=CC=3)F)N(C)C(=O)C(C)=C2N1C(C=1)=CC=CC=1NC(=O)C1(C)COC1 AWELVSKDGIEZGP-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN288KO2012 | 2012-03-14 | ||
| IN288/KOL/2012 | 2012-03-14 | ||
| PCT/IB2013/051915 WO2013136254A1 (en) | 2012-03-14 | 2013-03-11 | Heterocyclyl compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514056A JP2015514056A (ja) | 2015-05-18 |
| JP2015514056A5 true JP2015514056A5 (cg-RX-API-DMAC10.html) | 2016-04-28 |
| JP6093384B2 JP6093384B2 (ja) | 2017-03-08 |
Family
ID=47997632
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561564A Active JP6431770B2 (ja) | 2012-03-14 | 2013-03-11 | Ｍｅｋインヒビターとしてのヘテロシクリル化合物 |
| JP2014561567A Active JP6093384B2 (ja) | 2012-03-14 | 2013-03-11 | ヘテロシクリル化合物 |
| JP2018088389A Active JP6630771B2 (ja) | 2012-03-14 | 2018-05-01 | Ｍｅｋインヒビターとしてのヘテロシクリル化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561564A Active JP6431770B2 (ja) | 2012-03-14 | 2013-03-11 | Ｍｅｋインヒビターとしてのヘテロシクリル化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018088389A Active JP6630771B2 (ja) | 2012-03-14 | 2018-05-01 | Ｍｅｋインヒビターとしてのヘテロシクリル化合物 |
Country Status (35)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| GEP201706774B (en) | 2012-03-14 | 2017-11-27 | Lupin Ltd | Heterocyclyl compounds |
| CN107652289B (zh) | 2012-06-13 | 2020-07-21 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| JP6449244B2 (ja) | 2013-04-19 | 2019-01-09 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｆｇｆｒ抑制剤としての二環式複素環 |
| KR102222569B1 (ko) * | 2013-10-25 | 2021-03-05 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 피리딘의 케톤 유도체의 제조 방법 및 제약 용도 |
| WO2016009306A1 (en) * | 2014-07-15 | 2016-01-21 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
| WO2016035008A1 (en) * | 2014-09-04 | 2016-03-10 | Lupin Limited | Pyridopyrimidine derivatives as mek inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| JP7219218B2 (ja) | 2016-12-22 | 2023-02-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| TWI870922B (zh) * | 2017-12-21 | 2025-01-21 | 德商百靈佳殷格翰國際股份有限公司 | 作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物 |
| CN119241541A (zh) | 2018-05-04 | 2025-01-03 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| JP2022537044A (ja) | 2019-06-19 | 2022-08-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗がん併用療法 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4003356A1 (en) * | 2019-07-30 | 2022-06-01 | Edvince AB | Mek inhibitor for treatment of stroke |
| EP3797899A1 (de) | 2019-09-27 | 2021-03-31 | Primetals Technologies Austria GmbH | Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| IL293001A (en) | 2019-12-04 | 2022-07-01 | Incyte Corp | Derivatives of fgfr repressors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AU2021285032A1 (en) | 2020-06-02 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| CN117479942A (zh) | 2021-04-09 | 2024-01-30 | 勃林格殷格翰国际有限公司 | 抗癌疗法 |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| IL307673A (en) * | 2021-04-16 | 2023-12-01 | Ikena Oncology Inc | MEK inhibitors and their use |
| JP2024521788A (ja) | 2021-05-27 | 2024-06-04 | ミラティ セラピューティクス， インコーポレイテッド | 併用療法 |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US20250129095A1 (en) | 2021-12-01 | 2025-04-24 | Boehringer Ingelheim Int'l GmbH Corp. | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| EP4441051A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
| PE20241356A1 (es) | 2021-12-01 | 2024-07-03 | Boehringer Ingelheim Int | Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer |
| WO2023099623A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| JP2024543976A (ja) | 2021-12-01 | 2024-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体 |
| CN114456166B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用 |
| CN114573582B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用 |
| CN114605408B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用 |
| CN114573581B (zh) * | 2022-03-30 | 2023-09-01 | 沈阳药科大学 | 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用 |
| KR20250040894A (ko) | 2022-05-25 | 2025-03-25 | 이케나 온콜로지, 인코포레이티드 | Mek 억제제 및 이의 용도 |
| WO2024246099A1 (en) | 2023-05-30 | 2024-12-05 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| UA72612C2 (en) * | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| US6825180B2 (en) * | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
| GB0129099D0 (en) | 2001-12-05 | 2002-01-23 | Astrazeneca Ab | Chemical compounds |
| GEP20063909B (en) * | 2002-01-22 | 2006-08-25 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| AU2004293018B2 (en) | 2003-11-19 | 2010-02-18 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| PL2298768T3 (pl) * | 2004-06-11 | 2013-03-29 | Japan Tobacco Inc | Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| AU2009344690A1 (en) | 2009-04-21 | 2011-10-27 | Novartis Ag | Heterocyclic compounds as MEK inhibitors |
| GEP201706774B (en) | 2012-03-14 | 2017-11-27 | Lupin Ltd | Heterocyclyl compounds |
-
2013
- 2013-03-11 GE GEAP201313596A patent/GEP201706774B/en unknown
- 2013-03-11 EA EA201491672A patent/EA028232B1/ru unknown
- 2013-03-11 GE GEAP201313595A patent/GEP201706671B/en unknown
- 2013-03-11 KR KR1020147028557A patent/KR20140138911A/ko not_active Ceased
- 2013-03-11 SG SG11201405006PA patent/SG11201405006PA/en unknown
- 2013-03-11 US US14/385,106 patent/US9573944B2/en active Active
- 2013-03-11 DK DK13712929.2T patent/DK2834237T3/en active
- 2013-03-11 EP EP13711973.1A patent/EP2834236B1/en active Active
- 2013-03-11 EA EA201491671A patent/EA029768B1/ru unknown
- 2013-03-11 PL PL13712929T patent/PL2834237T3/pl unknown
- 2013-03-11 NZ NZ629432A patent/NZ629432A/en unknown
- 2013-03-11 IN IN1755MUN2014 patent/IN2014MN01755A/en unknown
- 2013-03-11 AU AU2013234009A patent/AU2013234009B2/en active Active
- 2013-03-11 CU CUP2014000109A patent/CU24335B1/es unknown
- 2013-03-11 MY MYPI2014002639A patent/MY174188A/en unknown
- 2013-03-11 AP AP2014008009A patent/AP3859A/en active
- 2013-03-11 DK DK13711973.1T patent/DK2834236T3/da active
- 2013-03-11 EP EP13712929.2A patent/EP2834237B1/en active Active
- 2013-03-11 MX MX2014010925A patent/MX355526B/es active IP Right Grant
- 2013-03-11 CU CUP2014000110A patent/CU24272B1/xx unknown
- 2013-03-11 JP JP2014561564A patent/JP6431770B2/ja active Active
- 2013-03-11 ES ES13712929T patent/ES2684517T3/es active Active
- 2013-03-11 AP AP2014008008A patent/AP3834A/en active
- 2013-03-11 UA UAA201411014A patent/UA114907C2/uk unknown
- 2013-03-11 PE PE2014001400A patent/PE20141974A1/es active IP Right Grant
- 2013-03-11 US US14/385,092 patent/US9428499B2/en active Active
- 2013-03-11 CN CN201710823363.9A patent/CN107698585A/zh active Pending
- 2013-03-11 JP JP2014561567A patent/JP6093384B2/ja active Active
- 2013-03-11 KR KR1020197024543A patent/KR102241111B1/ko active Active
- 2013-03-11 CN CN201810086896.8A patent/CN108383836B/zh active Active
- 2013-03-11 TR TR2018/11976T patent/TR201811976T4/tr unknown
- 2013-03-11 MY MYPI2014002638A patent/MY175950A/en unknown
- 2013-03-11 AU AU2013234014A patent/AU2013234014B2/en not_active Ceased
- 2013-03-11 PE PE2014001399A patent/PE20141973A1/es active IP Right Grant
- 2013-03-11 CA CA2865164A patent/CA2865164C/en active Active
- 2013-03-11 SG SG11201405007QA patent/SG11201405007QA/en unknown
- 2013-03-11 MA MA37405A patent/MA37405A1/fr unknown
- 2013-03-11 UA UAA201411011A patent/UA114906C2/uk unknown
- 2013-03-11 ES ES13711973T patent/ES2741896T3/es active Active
- 2013-03-11 WO PCT/IB2013/051908 patent/WO2013136249A1/en not_active Ceased
- 2013-03-11 MX MX2014010928A patent/MX355474B/es active IP Right Grant
- 2013-03-11 MA MA37400A patent/MA37400B1/fr unknown
- 2013-03-11 CN CN201380014210.XA patent/CN104203947A/zh active Pending
- 2013-03-11 NZ NZ629442A patent/NZ629442A/en not_active IP Right Cessation
- 2013-03-11 CN CN201380023296.2A patent/CN104271577A/zh active Pending
- 2013-03-11 KR KR1020197017334A patent/KR102240101B1/ko not_active Expired - Fee Related
- 2013-03-11 WO PCT/IB2013/051915 patent/WO2013136254A1/en not_active Ceased
- 2013-03-11 BR BR112014022713-6A patent/BR112014022713B1/pt active IP Right Grant
- 2013-03-11 CA CA2865167A patent/CA2865167C/en not_active Expired - Fee Related
- 2013-03-11 KR KR1020147028556A patent/KR20140138910A/ko not_active Ceased
- 2013-03-11 MX MX2018003665A patent/MX366426B/es unknown
- 2013-03-11 IN IN1754MUN2014 patent/IN2014MN01754A/en unknown
-
2014
- 2014-08-18 TN TNP2014000357A patent/TN2014000357A1/fr unknown
- 2014-08-18 TN TNP2014000356A patent/TN2014000356A1/fr unknown
- 2014-08-22 ZA ZA2014/06186A patent/ZA201406186B/en unknown
- 2014-09-09 IL IL234559A patent/IL234559A/en active IP Right Grant
- 2014-09-09 IL IL234560A patent/IL234560A/en active IP Right Grant
- 2014-09-10 DO DO2014000203A patent/DOP2014000203A/es unknown
- 2014-09-10 DO DO2014000204A patent/DOP2014000204A/es unknown
- 2014-09-11 NI NI201400107A patent/NI201400107A/es unknown
- 2014-09-11 NI NI201400108A patent/NI201400108A/es unknown
- 2014-09-12 PH PH12014502041A patent/PH12014502041B1/en unknown
- 2014-09-12 GT GT201400195A patent/GT201400195A/es unknown
- 2014-09-12 PH PH12014502040A patent/PH12014502040A1/en unknown
- 2014-09-12 CL CL2014002412A patent/CL2014002412A1/es unknown
- 2014-09-12 CL CL2014002411A patent/CL2014002411A1/es unknown
- 2014-09-12 GT GT201400196A patent/GT201400196A/es unknown
- 2014-10-06 CO CO14221195A patent/CO7160029A2/es unknown
- 2014-10-06 CO CO14221191A patent/CO7170131A2/es unknown
- 2014-10-06 CR CR20140463A patent/CR20140463A/es unknown
- 2014-10-06 CR CR20140464A patent/CR20140464A/es unknown
-
2016
- 2016-07-25 US US15/218,980 patent/US9555035B2/en active Active
- 2016-12-22 US US15/388,327 patent/US9969731B2/en active Active
-
2017
- 2017-01-06 US US15/400,627 patent/US9827247B2/en active Active
- 2017-01-25 AU AU2017200493A patent/AU2017200493B2/en active Active
-
2018
- 2018-04-12 AU AU2018202568A patent/AU2018202568B2/en active Active
- 2018-05-01 JP JP2018088389A patent/JP6630771B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514056A5 (cg-RX-API-DMAC10.html) | ||
| JP2015509975A5 (cg-RX-API-DMAC10.html) | ||
| JP6196156B2 (ja) | 過剰増殖性障害および血管新生に関連する疾患の治療のために有用なアミノアルコール置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン誘導体 | |
| CL2013003647A1 (es) | Compuestos derivados de pirrolo[2,3-d] pirimidina o pirrolo[2,3-b]piridina, inhibidores de la actividad de jak; composicion farmaceutica; utiles para el tratamiento de enfermedades autoinmunitarias, inflamatorias y de reabsorcion osea, cancer, trastornos mieloproliferativos o rechazo a trasplante de organos. | |
| JP2016528197A5 (cg-RX-API-DMAC10.html) | ||
| NZ629432A (en) | Heterocyclyl compounds as mek inhibitors | |
| FI3932919T3 (fi) | Jak-inhibiittoriyhdiste ja sen käyttö | |
| JP2009538897A5 (cg-RX-API-DMAC10.html) | ||
| JP2007505933A5 (cg-RX-API-DMAC10.html) | ||
| JP2012501312A5 (cg-RX-API-DMAC10.html) | ||
| JP2016518324A5 (cg-RX-API-DMAC10.html) | ||
| RU2009113612A (ru) | Ацетамидные производные хиназолинона и изохинолинона | |
| JP2016522835A5 (cg-RX-API-DMAC10.html) | ||
| MA38323A1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| JP2016530283A5 (cg-RX-API-DMAC10.html) | ||
| JP2017071634A5 (cg-RX-API-DMAC10.html) | ||
| JP2014511892A5 (cg-RX-API-DMAC10.html) | ||
| JP2000086657A5 (cg-RX-API-DMAC10.html) | ||
| JP2008535902A5 (cg-RX-API-DMAC10.html) | ||
| JP2015527401A5 (cg-RX-API-DMAC10.html) | ||
| AR107751A1 (es) | Composiciones de forma de dosificación que comprenden un inhibidor de tirosina cinasa de bruton | |
| ES2639402T3 (es) | 2,3-dihidroimidazo[1,2-c]quinolinas sustituidas con arilaminoalcohol | |
| JP2009532452A5 (cg-RX-API-DMAC10.html) | ||
| RU2014115476A (ru) | Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ | |
| JP2016540803A5 (cg-RX-API-DMAC10.html) |